Hetero Biopharma gets nod for Sputnik phase-3 trials

The RDIF has signed agreements with several companies to manufacture Sputnik V in India — Virchow Biotech (up to 200 million doses per year) Gland Pharma (252 million doses) and Stelis Biopharma (200 million doses).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2SNzLSn
via IFTTT